VOOPOO
16.3.2022 11:24:08 CET | Business Wire | Press release
VOOPOO, a leading vape manufacturer, recently released a review on its development, revealing the underlying driving force of its success against the market backdrop of complicated international relationships, rising operation cost, intensifying competition, and product similarity – the four major innovation models, namely technological innovation to provide long-term momentum, system innovation to ensure lasting vitality, operating innovation to expand company footprint, and product innovation to increase market share.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220310006062/en/
Innovation Model 1 - Technological innovation to provide long-term momentum
Technological innovation, as the foundation, provides a steady impetus for development. VOOPOO has established the strategic concept of investing in technological innovation and developing leading and original technologies.
In 2017, VOOPOO creatively developed the GENE series chips, and collaborated with DRAG to set the world record for fastest ignition speed at that time. Products were loved by more than 4 million users around the world, and are still regarded as an industry icon. In 2019, the innovative size-compatible VINCI became a new trend in Mod Pod. In 2020, DRAG X/S became one of the best-sellers in the world with its super performance and innovative metal-leather design. In 2021, VOOPOO innovatively explored the PNP/TPP/ITO vape platforms, starting to set the new technical standards in the industry.
It is with in-depth research and systematic control of market segments, keen focus on products and technologies, the pioneering and innovative spirit, and the belief in technological innovation, that VOOPOO has proceeded forward in the global market and won the trust of global users.
Since scientific and technological innovation is the primary productive force of an enterprise and the only way to achieve a global leading position, VOOPOO has set up the global innovation center with more than 500 R&D technicians working on projects at the same time. VOOPOO’s innovation model will bring the company more technological breakthroughs and promote the implementation and development of its global strategy.
Innovation Model 2 – System innovation to ensure lasting vitality
System innovation, as the soul, builds an open innovation platform, forms a sound structure from the entire group to each business department, and creates a high-value model for enterprise development. VOOPOO implements a four-level R&D system from research to product development: an innovative platform model integrating research institute, PhD researchers, expert consultants, and innovation projects covering multiple fields such as basic research, new materials, innovative atomization, HNB technology, intelligent manufacturing and modern logistics.
As of 2022, VOOPOO has applied for more than 1,000 cases of intellectual property, and has 3 R&D centers around the world covering basic research, vaping innovation, chip technology, and life science. In addition, VOOPOO has built 6 manufacturing and processing centers which are in line with Good Manufacturing Practice (GMP), covering a total area of 120,000 square meters. At the same time, VOOPOO also cooperates with many universities on innovative materials to build a forward-looking R&D system integrating production, academy and research.
In order to protect independent intellectual property rights and also stimulate creativity, VOOPOO has established a global, full-service, full-process intellectual property management system. In view of the increasing number of competitors and competitive products as well as the rampant counterfeiting, VOOPOO has applied for nearly 600 trademarks around the world, and registered defensive trademarks at the same time to prevent preemptive registration of the same or similar trademarks by third parties, so as to avoid “free riders”, thereby defending the company’s brand and reputation.
In March 2022, VOOPOO’s core trademark was included in the “2021 Guangdong Provincial Key Trademark Protection List”. It is worth noting that among the 580 trademarks on the list, only 3 are from the vaping industry.
In addition, in order to promote compliance and standardization in the global market, VOOPOO implemented the compliance strategy and set up the global compliance department early in 2019. VOOPOO was also deeply engaged in the compilation of China’s GB standard, and has submitted the American PMTA (VOOPOO is among the first batch of PMTA applicants) and involved in the European TPD3 standards.
Innovation Model 3 – Operating innovation to expand company footprint
Operating innovation, as the effective means, enables the company to be open-minded, share resources, build industrial chains, and achieve further growth.
In the Era 1.0 of operation, the upstream is about production, the midstream is about marketing, and the downstream is about channels. They are clearly distinctive to each other and each part can profit greatly. In the Era 2.0, upstream, midstream and downstream obviously become inseparable. Production, marketing and channels are closely intertwined. The ecology of the full industry chain reflects the current strategic demand of terminal consumption, channel distribution and transboundary cooperation.
Based on industry needs, VOOPOO has built the diversified strategic business structure to fully serve the needs of all parties. The company has formed a full industrial chain of vape integrating R&D, production, branding and channels, and has achieved differentiated, unique and irreproducible advantages through the integration of the industrial value chain.
At present, VOOPOO has established absolute market competitiveness on a global scale with more than 200 reserve products every year for different markets in the world. Within 3 years, it has established long-term cooperation relationships with partners in more than 70 countries and regions, and opened 6 overseas branches focusing on localized operations in the United States, UK, Indonesia, Canada and other countries. It has set up a network of 100,000 outlets around the world to shape its global brand influence.
Innovation Model 4 – Product innovation to increase market share
The VOOPOO-style innovation is ultimately product innovation, which further brings VOOPOO a more solid market position.
In the previous 2021 Ecigclick Vape Awards, VOOPOO won the Best Vape Kit For Beginners, the Best POD, the Best MOD, and the Best Sub Ohm Tank respectively with its four products ARGUS, DRAG Nano 2, DRAG 3, TPP-X. The awards reflected VOOPOO’s user-oriented consumer insights and diversified product innovation.
With the evolution of the market environment and technological innovation, users’ demands for vaping products are also constantly upgrading, and scenario-based, lightweight and multi-functional products are increasingly favored by the market. In view of this and driven by user value, VOOPOO decided to enter a new era by launching a portfolio comprising four core product series, DRAG, VINCI, ARGUS, and V, to provide users with more accurate product solutions and to continue to upgrade user experience and explore the global market.
Adhering to the four models, VOOPOO-style innovation has set a good example for the development of vaping companies.
In today’s fast-changing world, long-term thinking for the future is becoming more and more important. VOOPOO will continue to pursue the value guided by the long-term thinking. Confronted with the obstacles commonly shared by the industry, VOOPOO is taking a unique path of innovation development.
“Long-term investment in technological innovation should be planned in a long-term manner. We must dare to embrace uncertainty and strengthen cooperation with partners to truly realize the integration from technology to products,” noted EVEREST, Founder and CEO of VOOPOO.
VOOPOO firmly believes that good products are the foundation of the sustainable development of the industry. The company should be a friend of time and a pioneer of technology, and work with users and partners to jointly drive the sustainable development of the industry. The future will definitely belong to long-termism, and VOOPOO look forward to engaging more partners in its development.
WARNING: This product may be used with e-liquid products containing nicotine. Nicotine is an addictive chemical.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220310006062/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
